PEP-Therapy is pioneering the use of innovative peptides as targeted therapies for oncology, with a primary focus on their lead product, PEP-010. This first-in-class therapeutic peptide operates by dissociating the interaction between two critical proteins in the apoptotic pathway: Caspase-9 and PP2A. By releasing these proteins, PEP-010 aims to restore normal apoptosis in cancer cells, thereby promoting physiological cell death. The peptide is designed using a patented technology known as CP&IP (Cell Penetrating & Interfering Peptides), which combines an optimized Cell-Penetrating Peptide (CPP) to facilitate cellular delivery and a short Interfering Peptide that disrupts protein-protein interactions. This dual functionality allows PEP-010 to inhibit key pathological mechanisms while preserving normal physiological processes.

Currently, PEP-010 is undergoing a Phase Ia/b clinical trial targeting advanced solid tumors, particularly platinum-resistant ovarian cancer and pancreatic ductal adenocarcinoma. The trial has demonstrated favorable safety and tolerability profiles, with encouraging preliminary signals of antitumor activity observed in patients. Notably, PEP-010 has shown significant tumor growth inhibition in preclinical models, achieving up to 85% inhibition in breast and ovarian Patient Derived Xenograft (PDX) models. The ongoing research aims to further validate these findings and explore the potential of PEP-010 in combination with standard chemotherapy agents, thereby expanding the therapeutic options available for patients with resistant forms of cancer.

France

PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology.

PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.

PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.



PEP-Therapy

Company Details